ProSensa Holding N.V. (RNA) to Host Conference Call to Discuss Recent Drisapersen Data Presentations
10/4/2013 9:31:22 AM
Leiden, The Netherlands, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, will hold a conference call on Tuesday, October 8, 2013 at 11:00 a.m. ET / 5:00 p.m. CET to discuss recently-presented data on drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, which is exclusively licensed to GlaxoSmithKline (GSK).
Help employers find you! Check out all the jobs and post your resume.